Reports


Anti-infective Agents Market Size & Share, Sector / Industry Report & Analysis, 2019-2025 (Includes Business Impact of COVID-19)

  • TBI169676
  • August 01, 2019
  • Global
  • 132 pages
  • HCCResearch
                                              Abstract, Snapshot, Market Analysis & Market Definition: Global Anti-infective Agents Market

The global anti-infective agents market size was valued at USD 111.1 billion in 2018 and is anticipated to expand at a CAGR of 3.4% during the forecast period. Extensive R&D efforts pertaining to the development of new drugs with high efficacy and potency against multi-drug resistant micro-organisms is one of the major factors stimulating the growth.
New drug approvals are also estimated to accentuate the market growth over the forecast period. For instance, in 2016, the Food and Drug Administration (FDA) approved drugs, such as Descovy by Gilead, for the treatment of HIV-1 infection and Zepatier by Merck that targets chronic Hepatitis C virus (HCV) genotypes 1 or 4 infection in adults.
 
Factors like increasing prevalence of infectious diseases and antimicrobial resistance to existing anti-infective agents are estimated to fuel the market growth. Moreover, escalating health-consciousness, with regard to the availability of diagnostics for infectious diseases and avoidable risks associated with early diagnosis are some of the factors projected to boost the growth.
Companies have recently launched a panel of FDA approved, modified antibiotics for their use in the treatment of acute bacterial skin and soft tissue infections; these drugs include Dalvance (Dalbavancin), Orbactiv (Oritavancin), Sivextro (Tedizolid), and Zevtera (Ceftobiprole). The high penetration of these anti-infective drugs due to their increased efficacy is expected to serve as a growth driver for the anti-infective agents market in the forthcoming years.
Commercialization of pipeline anti-infective drugs is also estimated to be a key factor strengthening the growth. In 2015, a recently introduced anti-fungal drug, Cresemba, marketed by Astellas Pharma U.S., Inc. gained FDA approval. The clinical trials revealed that the drug demonstrated significant efficacy for the treatment of invasive mucormycosis and invasive aspergillosis.

Market Segmentation, Outlook & Viewpoint: Global Anti-infective Agents Market


Type Market Segmentation & Outlook (Revenue, USD Billion; 2013 - 2026)

Antibacterial

Antiviral

Antifungal


Antibacterial Drug Class Market Segmentation & Outlook (Revenue, USD Billion, 2013 - 2026)

Cephalosporins

Penicillin

Fluoroquinolones

Macrolides

Carbapenem

Others


Antibacterial Route of Administration Market Segmentation & Outlook (Revenue, USD Billion, 2013 - 2026)

Topical

Oral

IV

Others


Antifungal Drug Class Market Segmentation & Outlook (Revenue, USD Billion, 2013 - 2026)

Azoles

Echinocandins

Polyenes

Others


Antifungal Route of Administration Market Segmentation & Outlook (Revenue, USD Billion, 2013 - 2026)

Topical

Oral

IV

Others


Antiviral Route of Administration Market Segmentation & Outlook (Revenue, USD Billion, 2013 - 2026)

Topical

Oral

IV

Others


Route of Administration Market Segmentation & Outlook (Revenue, USD Billion, 2013 - 2026)

Topical

Oral

IV

Others


Distribution Channel Market Segmentation & Outlook (Revenue, USD Billion, 2013 - 2026)

Hospital Pharmacies

Retail Pharmacies

Specialty Pharmacies

e-Commerce

Others


Key Players, Recent Developments & Regional Insights: Global Anti-infective Agents Market


On the basis of type, the market is categorized into antibacterial, antifungal, and antiviral drugs. The anti-bacterial segment generated over USD 45.3 billion in 2018, attributed to the high prescription of these products and the broad-spectrum activity of cephalosporin and penicillin.
The anti-fungal agent segment is further classified into azoles, echinocandins, and polyenes. Amongst these, Azoles are estimated to hold the largest market share over the forecast period owing to their high ability to combat systemic fungal infections.
However, the anti-viral agent segment is anticipated to exhibit a sharp increase in growth in the coming decade owing to the introduction of novel drugs and the large patient population suffering from viral infections that require long treatment procedures. Furthermore, government collaborations with pharmaceutical companies for the development of new drugs are anticipated to support the segment growth.
Route of Administration Insights
On the basis of route of administration, the market is categorized into topical, oral, and intravenous (IV). Oral route of administration held the largest market share in 2018 owing to new product development and presence of strong pipeline. Oral therapies minimize the use of central lines for intravenous drug administration and complications associated with it and reduce hospital stays.
Intravenous segment is estimated to exhibit lucrative growth over the forecast period owing to high efficacy, better rate of bioavailability, and rapid delivery of drugs offered by this route of administration. It is widely used owing to the control it provides over the dosage and rapid delivery of drugs. Intravenous routes have a higher rate of bioavailability than other routes of administration.
Distribution Channel Insights
Key distribution channels include hospital pharmacy, retail pharmacy, specialty pharmacy, and e-commerce. Hospital pharmacy led the segment in 2018 owing to the increasing number of hospitalizations worldwide. Moreover, hospitals provide extensive patient treatment, care, quick reimbursement, and insurance policies owing to which patients opt for hospital pharmacies.
 
E-commerce was expected to witness exponential CAGR over the forecast period owing to comfort, flexibility, and convenience as compared to other distribution channels. Various factors such as convenience of purchasing and improving healthcare infrastructure in developing regions are likely to have a positive impact on the growth.

Regional Insights
North America was one of the leading regions in 2018 with a revenue generation of over USD 29.87 billion. Presence of sophisticated healthcare infrastructure and high awareness among end-users such as clinicians and healthcare professionals are estimated to be the key growth drivers. Moreover, high purchasing power for expensive drugs and the presence of favorable reimbursement policies are anticipated to further fuel the regional market during the forecast period.
Asia-Pacific is expected to witness significant CAGR over the forecast period owing to the presence of generics companies and rising economic stability and increasing disposable income. In addition, growing geriatric population coupled with increased susceptibility to infections is expected to provide a potential growth platform in the forthcoming years.
Anti-infective Agents Market Share Insights
Some of the key players are GlaxoSmithKline plc.; Pfizer Inc.; Bayer AG; Sanofi; Merck & Co., Inc.; Bristol-Myers Squibb Company; Abbott; Novartis AG; Johnson & Johnson Services Inc.; Gilead Sciences, Inc.; and Astellas Pharma Inc.
Most companies are expanding their product portfolios by focusing on untapped opportunities. For instance, Gilead launched Sovaldi, the first-ever oral medication for the treatment of HCV genotype 2 and 3 in 2013.
The key players are also implementing certain competitive strategies such as mergers, acquisitions, and collaborations to gain greater market share. In December 2015, Evotec AG and Spero Therapeutics announced the extension of their collaboration for the development of novel anti-bacterial drugs.

Key Insights Covered: Global Anti-infective Agents Market
1.  North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Anti-infective Agents industry.
2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Anti-infective Agents industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Anti-infective Agents industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Anti-infective Agents industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Anti-infective Agents industry.

Research Methodology: Global Anti-infective Agents Market
  • Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  • Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  • Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other

Table of Content
Chapter 1. Methodology and Scope
    1.1. Market segmentation & scope
    1.2. Market definition
    1.3. Information procurement
         1.3.1. Purchased database
         1.3.2. HCC’s Internal Database
         1.3.3. Secondary sources & third-party perspectives
         1.3.4. Primary research
    1.4. Information analysis
         1.4.1. Data analysis models
    1.5. Market formulation & data visualization
    1.6. Data validation & publishingChapter 2. Executive Summary
    2.1. Market Outlook 
    2.2. Segment Outlook 
    2.3. Competitive InsightsChapter 3. Global Anti
|  read more...

Request a sample

Fill below form to request a sample

Enquiry

Please fill this form to enquire before buying

Discount

You can request for discount regarding the report by using below form